Thyrotoxicosis: A Rare Presenting Symptom of Hurthle Cell Carcinoma of the Thyroid

Clinical Nuclear Medicine

Volumn 28, Issue 10, 2003, Pages 803-806

  Wong, C P ^a   AuYong, T K ^a   Tong, C M ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Hurthle cell carcinoma; Scintigraphy; Thyrotoxicosis

Indexed keywords

DIAGNOSTIC AGENT; PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENTAL FINDING; ONCOCYTOMA; PATHOLOGY; RARE DISEASE; SCINTISCANNING; SYMPTOMATOLOGY; THYROID CARCINOMA; THYROID NODULE; THYROID PARAFOLLICULAR CELL; THYROID SCINTISCANNING; THYROID TUMOR; THYROTOXICOSIS;

ADENOMA, OXYPHILIC; AGED; FEMALE; HUMANS; INCIDENTAL FINDINGS; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; THYROID NEOPLASMS; THYROTOXICOSIS;

EID: 1442333846     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000089667.15648.e9     Document Type: Article

References (18)

1. The Papanicolaou Society of Cytopathology Task Force on Standards of Practices. January 17, 1996.
2. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol. 2001;19.
3. Masood S, Auguste LJ, Westerband A, et al. Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. Am J Surg. 1993;166:366-368.
4. Caplan RH, Abellera RM, Kisken WA. Hurthle cell neoplasms of the thyroid gland: reassessment of functional capacity. Thyroid. 1994;4: 243-248.
5. Yutan E, Clark OH. Hurthle cell carcinoma. Curr Treat Options Oncol. 2001;2:331-335.
6. Katagiri M, Suzuki S, Sadahiro S. Accumulation of iodine-131 and technetium-99m pertechnetate in thyroid carcinoma. Clin Nucl Med. 1988;13:276-379.
7. Szonyi G, Bowers P, Allwright S. A comparative study of 99mTc and 131I in thyroid scanning. Eur J Nucl Med. 1982;7:444-556.
8. Hirabayashi S, Koga Y. Inconsistent images of thyroid nodule scintigrams made with iodine and pertechnetate: case report. J Nucl Med. 1975;16:918.
9. Lupi A, Orsolon P. 'Hot' carcinoma of the thyroid. Case reports and comments on the literature. Minerva Endocrinol. 2002;27:53-57.
10. Siddiqui AR, Karanauskas S. Hurthle cell carcinoma in an autonomous thyroid nodule in an adolescent. Pediatr Radiol. 1995;25:568-569.
11. Russo D, Wong MG, Costante G. A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid. 1999;9:13-17.
12. Yen TC, Lin HD, et al. The role of technetium-99m sestamibi wholebody scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans. Eur J Nucl Med. 1994;21:980-983.
13. Wilson CJ, Woodroof JM, Girod DA. First report of Hurthle cell carcinoma revealed by octreotide scanning. Ann Otol Rhinol Laryngol. 1998;107:847-850.
14. Gulec SA, Serafini AN, Sridhar KS. Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med. 1998;39:243-245.
15. Tisell LE, Ahlman H, et al. Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid. Br J Cancer. 1999;79: 1579-1582.
16. Soler C, Caillot-Augusseau A, Moncet M, et al. Metastases of Hurthle cell carcinoma of the thyroid depicted by Tc 99m sestamibi. Clin Nucl Med. 1999;24:798-800.
17. Blount CL, Dworkin HJ. F-18 FDG uptake by recurrent Hurthle cell carcinoma of the thyroid using high energy planar scintigraphy. Clin Nucl Med. 1996;21:831-833.
18. Chen H, Nicol TL, Zeiger MA, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg. 1998;27.